MARY CHELF: Open Payments
NPI 1821617077 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,644 in 141 payments from 20 companies in 2025. Trend: 2023 $1,293 · 2024 $2,605 · 2025 $2,644
Food & beverage: $2,644
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $695 |
| Janssen Biotech, Inc. | 19 | $353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $294 |
| Madrigal Pharmaceuticals | 7 | $181 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $173 |
| Lilly USA, LLC | 6 | $148 |
| Regeneron Healthcare Solutions, Inc. | 6 | $137 |
| Biocon Biologics Inc | 5 | $98 |
| Gilead Sciences, Inc. | 4 | $92 |
| GENZYME CORPORATION | 4 | $78 |
Products named: RINVOQ, TREMFYA, ENTYVIO, DUPIXENT, REZDIFFRA, XIFAXAN, OMVOH, SKYRIZI.
Industry payments across OK — which companies pay providers there.
